Cargando…
Plasminogen Activator Inhibitor 1 (PAI-1) and Haematologic Parameters in HIV- Positive Patients on Protease Inhibitor-Based HAART Regimen: A Case-Control Study
Background: Human immunodeficiency virus (HIV) infection is associated with an increased risk of hypercoagulability and treatment with antiretroviral agents especially protease inhibitors has also been reported to contribute to this risk. Altered fibrinolytic activity is reported as a mechanism of i...
Autores principales: | Christopher, Chimeziem, Nwogoh, Benedict, Akaba, Kingsley, igwilo, Hilary, Abang, Roger |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9703161/ https://www.ncbi.nlm.nih.gov/pubmed/36411985 http://dx.doi.org/10.1177/10760296221126176 |
Ejemplares similares
-
Vitamin D Deficiency is Associated With Increased Plasminogen Activator Inhibitor 1/Plasminogen Activator Inhibitor 2 Ratio in Pregnancy
por: Andersen, Matilde Kanstrup, et al.
Publicado: (2023) -
Plasminogen activator inhibitor-1 (PAI-1) expression in endometriosis
por: Alotaibi, Fahad T., et al.
Publicado: (2019) -
Determination of von Willebrand factor level in patient with sickle cell diseasein vaso‐occlusive crisis
por: Akaba, Kingsley, et al.
Publicado: (2020) -
Genetics of Plasminogen Activator Inhibitor-1 (PAI-1) in a Ghanaian Population
por: White, Marquitta J., et al.
Publicado: (2015) -
Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas.
por: Bouchet, C., et al.
Publicado: (1994)